Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.
We send one confirmation email first. Only emails about PPCB, unsubscribe in one click. Privacy
PPCB holds $832,006 in cash and short-term investments (as of Jun 30, 2026) and burns about $1.4M/quarter from operations, an estimated runway of 1.8 months at that rate (BioRadar estimate, not company guidance).
Dilution pressure: 55 · Elevated
The foregoing raises substantial doubt about our ability to continue as a going concern for a period of 12 months from the issue date of this report.10-K, Sep 2026
Recent financing filings on SEC EDGAR:
Source: SEC EDGAR (XBRL cash flow and financing filings). Dilution Watch: every company ranked → · Get an alert when PPCB files for a raise →
The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for PPCB and every other ticker you follow. Card required, cancel anytime.
Start 7-day free trial →